GHRP-2 Does Not Affect Water-Regulating Hormone in Healthy Men
Background
Growth hormone-releasing peptide-2 (GHRP-2) is a synthetic secretagogue known for its potent ability to stimulate growth hormone (GH) release. However, some GH secretagogues can also influence the secretion of arginine vasopressin (AVP), also known as antidiuretic hormone (ADH), which plays a critical role in regulating the body's water balance and blood pressure. The potential for GHRP-2 to impact AVP levels was previously unknown, creating a knowledge gap regarding its full physiological effects and safety profile, especially concerning fluid homeostasis. This study aimed to determine if GHRP-2 administration stimulates AVP secretion in healthy individuals.
Results
The study confirmed that GHRP-2 effectively stimulated growth hormone release, showing a significant 5.2-fold increase in peak GH levels compared to placebo (p<0.001). However, despite this robust GH response, GHRP-2 had no significant impact on plasma AVP concentrations. >Plasma AVP levels remained remarkably stable throughout the 3-hour observation period in both the GHRP-2 and placebo groups, with no significant difference (p>0.05) observed from baseline or between the treatment arms. Specifically, the mean AVP levels in the GHRP-2 group fluctuated by less than 8% from baseline, mirroring the minor variations seen with placebo. This indicates that GHRP-2 does not trigger the release of this crucial fluid-regulating hormone in healthy men.
Why It Matters
This finding is highly significant for understanding the safety and physiological profile of GHRP-2, particularly regarding its potential therapeutic applications. The absence of AVP stimulation suggests that GHRP-2 is unlikely to cause adverse effects related to fluid retention, hyponatremia (low sodium), or blood pressure alterations, which can be concerns with other substances affecting AVP. This makes GHRP-2 a potentially safer option for conditions requiring GH stimulation, such as growth hormone deficiency, without compromising fluid balance. Future research should focus on long-term studies and investigations in patient populations to further confirm these safety implications and explore its clinical utility.